Publications and Presentations of the Tuberculosis Trials Consortium
(as of 1 February 2014)

I. Publications

1999

2001

2002


2003


2004

2005


2006


2007


2008


2009


2010


2011


2012


2013


2014


[Authors]. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine and Isoniazid for Latent Tuberculosis Infection. Journal of the Pediatric Infectious Diseases Society, in press.

II. Presentations and Abstracts

1997


1998


1999


Bock N, for the Tuberculosis Trials Consortium. Safety and tolerability of once-weekly rifapentine/isoniazid (INH) vs. twice-weekly rifampin/INH in the continuation phase therapy of pulmonary tuberculosis in HIV-negative adults in USPHS Study 22. Poster presentation, 30th IUATLD World Conference on Lung Health, Madrid (Spain), September 1999.

2000
A Vernon for the TB Trials Consortium. TBTC Study 22 (Rifapentine Trial): Preliminary Results in HIV-negative Patients. Invited presentation at Rifapentine Evening Symposium, Meeting of the European Region of the IUATLD, Budapest (Hungary), April 2000.


Burman W, for the Tuberculosis Trials Consortium. Should tuberculosis treatment be extended in selected patients? Data from TBTC Study 22 and review of previous studies (poster). 38th Annual IDSA Meeting, New Orleans LA, Sept 7-10, 2000


**2001**


2002


**2003**


**2004**


2005


2006


2007


2008


2009


2010


2011


Modeling the pharmacokinetics of rifapentine in TB patients receiving 600 mg daily. 4th International Workshop on Clinical Pharmacology of TB drugs. 2011.


2012


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). International AIDS Society, July 2012.


Sterling TR, Benson CA, Shang N, Villarino ME, the AIDS Clinical Trials Group, and the Tuberculosis Trials Consortium. Tolerability among HIV-infected persons of three months of once-weekly rifapentine + INH (3HP) vs. 9 months of daily INH (9H) for treatment of latent tuberculosis infection: The PREVENT TB Study (TBTC Study 26/ACTG 5259). IV Congreso Nacional de Gesida, Spain, November 2012.

2013


Kolwijck E, Friedrich SO, Venter A, van Ingen J, Diacon AH. Effect of culture supernatant containing resuscitation-promoting factors on the growth of M. tuberculosis from sputum samples collected during antituberculosis treatment. European Society for Clinical Microbiology and Infectious Diseases, April 27-30, 2013, Berlin, Germany.


Dooley K and Bliven-Sizemore E. Population pharmacokinetics of pyrazinamide. Presented at the Clinical Pharmacology of TB Drugs meeting, Sept 2013


Kolwijck E, Friedrich SO, Venter A, van Ingen J, Diacon AH. Effect of culture supernatant containing resuscitation-promoting factors on the growth of M. tuberculosis from sputum samples collected during antituberculosis treatment. European Society for Clinical Microbiology and Infectious Diseases, April 27-30, 2013, Berlin, Germany.


Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. 6th International Workshop on Clinical Pharmacology of TB Drugs, Sept 2013

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. Gates sponsored TB Modeling and Analysis Consortium meeting in Beijing, China

Weiner M and MacKenzie W. Substudy to characterize rifapentine pharmacokinetic (PK) parameters in patients with TB. Pharmacokinetics and pharmacodynamics of rifapentine and rifampin. CPTR meeting in Washington, DC - October, 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms containing escalating doses of rifapentine. Presentation, INTER-TB, St. George's University, 25 October 2013

Dorman S and Goldberg S. Study 29X, Phase 2 clinical trial, is to compare tolerability and safety of arms
III. Manuscripts and Presentations/Abstracts submitted or in preparation

A. Manuscripts


B. Presentations and Abstracts
